Top 7 Companies in AI in Drug Discovery Domain

Published: June 2026

The discovery of potential drug candidates has traditionally been a complex, and time-intensive process, often limited by inefficiencies, and a lack of real-time insights. However, the integration of artificial intelligence (AI) and advanced computational technologies is fundamentally transforming drug discovery. It helps in enhancing precision, reducing failure rates, and accelerating timelines. Notably, in target identification step, AI enables the rapid analysis of vast datasets (including scientific literature, genomics, and proteomics) to identify and validate biological targets. This helps in improving the understanding of disease mechanisms and facilitating hypothesis generation.

Subsequently, in hit and lead identification, AI-driven approaches such as machine learning models, virtual screening, and generative algorithms streamline the discovery and optimization of candidate molecules. Furthermore, during lead optimization, AI supports the refinement of molecular structures to enhance potency, selectivity, and pharmacokinetic and pharmacodynamic properties. This helps in significantly reducing the time required to advance candidates to preclinical stages. Overall, the adoption of AI across the key stages of drug discovery not only minimizes reliance on traditional methods but also enables a more data-driven, and scalable approach to drug discovery.

Roots Analysis has conducted an exhaustive study on AI In Drug Discovery Market featuring the current market landscape and future opportunity for the companies engaged in healthcare, over a span of next 10 years.

Seven Prominent Players in the AI Drug Discovery Landscape

1. BenevolentAI
2. Collaborations Pharmaceuticals
3. Genialis
4. Healx
5. Insilico Medicine
6. Optibrium
7. XtalPi

The figure below highlights the top 7 players in AI in Drug Discovery Domain:

Top Companies to watch AI in Drug Discovery Market

Interested in exploring other players involved in AI-based Drug Discovery, along with their recent initiatives?

Discover Below the Details on Top7 Players in AI-based Drug Discovery Market

Let us dive deep into the details of the top players in AI in drug discovery domain. These companies were chosen based on Roots Analysis’ proprietary company competitiveness analysis, taking into consideration technology portfolio strength and recent initiatives. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. BenevolentAI

Company Overview

BenevolentAI is a UK-based global leader in AI-driven drug discovery, serving biotechnology and pharmaceutical innovators. The company specializes in knowledge graph-powered platforms and machine learning algorithms, offering end-to-end solutions from novel target identification to lead optimization and clinical candidate selection. Further, BenevolentAI provides advanced capabilities in multi-omics data integration, disease biology modeling, compound repurposing, and de novo molecule designing. Moreover, by leveraging advanced computational infrastructure and strategic international partnerships, BenevolentAI accelerates therapeutic development across various indications, while maintaining rigorous scientific validation and regulatory preparedness.

AI-based Drug Discovery Platform Specific Details

The section provides information on the various platforms being offered by BenevolentAI, along with details on platform name, type of AI technology used, drug discovery stages supported, and type of molecule analyzed.

Platform Name: Benevolent Platform
Type of AI Technology Used: Machine Learning (Deep Learning) and Large Language Model
Drug Discovery Stages Supported: Target Identification / Validation, and Lead Identification / Optimization
Type of Molecule Analyzed: Small Molecules and Biologics

Recent Developments

BenevolentAI is recognized for delivering advanced AI platforms that accelerate drug discovery by uncovering novel therapeutic targets and biological insights across complex diseases, from neurodegenerative disorders to metabolic conditions. Notably, the company entered into collaboration with Sidra Medicine on October 2025, leveraging its Retrieve to Explain (R2E) AI model to investigate the ZFP57 gene as a potential biomarker and therapeutic target for Type 1 Diabetes, Gestational Diabetes Mellitus, and obesity-related diabetes prevalent in Qatar. Despite the fact that publicly available information is fairly limited, the firm is anticipated to introduce additional AI-driven partnerships in the future to further advance its drug discovery portfolio.

To know more about the recent initiatives of BenevolentAI and other players in AI in drug discovery domain, access full report.

2. Collaborations Pharmaceuticals

Company Overview

Collaborations Pharmaceuticals is a US based company that deploys computational approaches and AI-based technologies for drug discovery and development. The firm partners with academic institutions and other leading companies to conduct research and identify early preclinical to clinical stage candidates for rare and neglected disorders. Moreover, the firm works with contract research organizations to predict target models and provide ADME data to accelerate their internal drug discovery programs. Further, the company generates revenue by providing contract services to its clients, including ADME models for rare disorders. Moreover, the firm aims to deliver AI expertise to clients to save costs and increase efficiency of the drug discovery and development process

AI-based Drug Discovery Platform Specific Details

The section provides information on the various platforms being offered by Collaborations Pharmaceuticals, along with details on platform name, type of AI technology used, drug discovery stages supported, and type of molecule analyzed.

Platform Name: MegaTox, MegaPredict, Assay Central, UV adVISor, MegaSyn, Mega AChE
Type of AI Technology Used: Machine Learning (Deep Learning, Supervised Learning, Reinforcement Learning)
Drug Discovery Stages Supported: Target Identification / Validation, and Lead Identification / Optimization
Type of Molecule Analyzed: Small Molecules

Recent Developments

In January 2026, the company entered into a partnership with Bausch + Lomb in order to apply its AI machine learning tools and expertise for identifying novel drugs for eye diseases.

To know more about the recent initiatives of Collaborations Pharmaceuticals and other players in AI in drug discovery domain, access full report.

3. Genialis

Company Overview

Genialis is a precision oncology company specializing in RNA biomarkers and AI-driven insights to match cancer patients with effective therapies. By leveraging the world's most diverse cancer datasets, its AI "supermodel" predicts therapeutic responses, explains mechanisms of action, and identifies resistance patterns for targeted inhibitors and immunotherapies. Further, the core ResponderID platform leverages machine learning models to segment patients by response characteristics and refine clinical trial parameters, reducing failure rates. This approach combines proprietary methodology with advanced AI to deliver actionable biomarkers, partnering with pharma leaders like Roche and Debiopharm.

AI-based Drug Discovery Platform Specific Details

The section provides information on the various platforms being offered by Genialis, along with details on platform name, type of AI technology used, drug discovery stages supported, and type of molecule analyzed.

Platform Name: ResponderID, Genialis Expressions, Genialis Supermodel
Type of AI Technology Used: Machine Learning
Drug Discovery Stages Supported: Target Identification / Validation, and Lead Identification / Optimization
Type of Molecule Analyzed: Small Molecules

Recent Developments

In January 2026, Genialis strengthened its multi-year collaboration with Debiopharm by deploying its Expressions platform to deliver a unified, AI-powered solution for biomarker discovery.

To know more about the recent initiatives of Genialis and other players in AI in drug discovery domain, access full report.

4. Healx

Company Overview

Healx is a UK-based leader in AI-driven drug discovery, focused on rare diseases and serving biotech / pharma innovators. The company specializes in the Healnet AI platform, combining knowledge graphs, causal reasoning, and machine learning for end-to-end solutions from target prioritization and drug repurposing to novel compound design. Further, Healx excels in analyzing millions of drug-disease data points, multi-omics integration, and mechanism-based hypothesis generation for precision therapies. Moreover, through advanced computational infrastructure and partnerships with patient foundations, Healx accelerates treatments across neurological, oncological, and metabolic disorders while emphasizing clinical validation and regulatory readiness.

AI-based Drug Discovery Platform Specific Details

The section provides information on the various platforms being offered by Healx, along with details on platform name, type of AI technology used, drug discovery stages supported, and type of molecule analyzed.

Platform Name: Healnet
Type of AI Technology Used: Machine Learning (Deep Learning) and Natural Language Processing
Drug Discovery Stages Supported: Target Identification / Validation, and Lead Identification / Optimization
Type of Molecule Analyzed: Small Molecules

Recent Developments

In September 2025, the company entered into a partnership with Vuja De Sciences. The aim of the partnership is to leverage its AI-powered platform for advancing HLX-4310, a clinical-stage program targeting metastatic osteosarcoma recurrence, strengthening its rare and pediatric oncology pipeline.

To know more about the recent initiatives of Healx and other players in AI in drug discovery domain, access full report.

5. Insilico Medicine

Company Overview

Insilico Medicine is a US–based clinical-stage biotech company focused on using artificial intelligence to accelerate end-to-end drug discovery and development. Its flagship platform integrates generative AI for de novo small-molecule design seamlessly combined with target identification, virtual screening, multi-parameter optimization, and automated synthesis within a closed-loop workflow. Further, company’s AI Chemistry42 is applied across multiple therapeutic areas, including oncological, fibrosis, immunological, and age-related diseases, to rapidly generate and prioritize novel, patentable candidates. Moreover, Insilico Medicine advances an internal pipeline of AI-discovered assets that have progressed from concept to clinical trials, demonstrating the translational potential of its platform.

AI-based Drug Discovery Platform Specific Details

The section provides information on the various platforms being offered by Insilico Medicine, along with details on platform name, type of AI technology used, drug discovery stages supported, and type of molecule analyzed.

Platform Name: Pharm.AI platform and Chemistry42
Type of AI Technology Used: Machine Learning (Deep Learning, Reinforcement Learning) and Generative AI
Drug Discovery Stages Supported: Target Identification / Validation, and Lead Identification / Optimization
Type of Molecule Analyzed: Small Molecules

Recent Developments

In January 2026, the company entered into a collaboration with Servier, leveraging its Pharma.AI platform along with latter company’s oncology expertise to discover and develop novel therapies.

To know more about the recent initiatives of Insilico Medicine and other players in AI in drug discovery domain, access full report.

6. Optibrium

Company Overview

Optibrium is a UK-based leader in AI-driven drug discovery, serving pharmaceutical and biotechnology innovators with computational platforms for small molecule design and optimization. The company specializes in StarDrop and Orion suites, offering end-to-end solutions from hit identification and lead optimization to ADMET prediction and scaffold hopping using machine learning and physics-based modeling.

Further, Optibrium excels in multi-parametric property optimization, matched molecular pair analysis, synthetic feasibility assessment, and automated design-make-test-analyze (DMTA) cycles. Moreover, by leveraging cloud-based AI integration and strategic pharma partnerships, Optibrium accelerates therapeutic development across oncological, CNS (central nervous system), and metabolic disorders, while ensuring drug-like properties and regulatory compliance.

AI-based Drug Discovery Platform Specific Details

The section provides information on the various platforms being offered by Optibrium, along with details on platform name, type of AI technology used, drug discovery stages supported, and type of molecule analyzed.

Platform Name: StarDrop, and Cerella
Type of AI Technology Used: Machine Learning (Deep Learning)
Drug Discovery Stages Supported: Lead Identification / Optimization
Type of Molecule Analyzed: Small Molecules

Recent Developments

In January 2026, the company appointed Nathan Brown as Director of Science, strengthening the company’s position in delivering scientifically rigorous software that addresses real-world efficiency and productivity challenges in molecular discovery.

To know more about the recent initiatives of Optibrium and other players in AI in drug discovery domain, access full report.

7. Xtalpi

Company Overview

XtalPi is a biotech pioneer, integrating quantum physics, AI, and robotics to revolutionize early-stage drug discovery and materials science. The company employs quantum algorithms for molecular structure calculations and proprietary AI large language models to screen billions of molecules, generating novel drug candidates. Further, its hybrid platform features an iterative feedback loop between cloud-based in silico simulations and robotic wet labs, accelerating hit-to-lead optimization and crystal structure prediction with significant accuracy. Notably, XtalPi has won multiple awards in 2025, including the ESG Pioneer 60 Annual Corporate ESG Practice Award and China Securities Journal's Golden Bull Award, recognizing its innovation, technological leadership, and long-term value across biopharma sector.

AI-based Drug Discovery Platform Specific Details

The section provides information on the various platforms being offered by Xtalpi, along with details on platform name, type of AI technology used, drug discovery stages supported, and type of molecule analyzed.

Platform Name: PepiX, Digital Drug Discovery and Development (ID4), and XtalFold
Type of AI Technology Used: Machine Learning (Deep Learning), and Large Language Model
Drug Discovery Stages Supported: Lead Identification / Optimization
Type of Molecule Analyzed: Small Molecules and Biologics

Recent Developments

In December 2025, the company entered into an agreement with Gan & Lee Pharmaceuticals in order to leverage former company’s proprietary AI peptide R&D platform (PepiX) for accelerating discovery and development of novel peptide drugs targeting metabolic diseases.

To know more about the recent initiatives of Xtalpi and other players in AI in drug discovery domain, access full report.

What About other Players in AI in Drug Discovery Market around the World?

The above article features the top 7 AI in drug discovery selected from a pool of 260 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Sources: